OSCROscar Health, Inc.

Healthcare

$30.99+47% 1Y

$30.99

$10.8552 weeks$34.17

Is the price fair?

Good

Undemanding: modest expectations priced in and cheap vs its sector.

2 good, 1 without data

What the price assumes~−28% a year

Priced for a decline (~−28% a year). The price demands less than its three-year revenue growth of 46% a year, expectations look modest.

Vs sector (EV/EBIT)2.3×

Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

All from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)middle of the market

FCF yieldtop 1% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What OSCR's price assumes

Oscar Health, Inc. trades at 23.8× earnings against 25.7× for the median Healthcare Plans name, cheaper than its own group.

23.8

Trailing P/E · Healthcare Plans median 25.7 · cheaper than the typical name in its group

Price / sales: 0.62
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 46%
Free cash flow yield · Healthcare Plans median 7.4%
Growth the price implies: −28%
Growth the price implies · The price pays for −28% free cash flow growth a year for a decade; the business has delivered +206% a year over the last three.